Cannabis and Epilepsy: The Epidiolex Story and What It Means

Balanced & Benefits

39%

A landmark 2017 trial in the New England Journal of Medicine found CBD reduced convulsive seizures by 39 percent in Dravet syndrome, paving the way for the first FDA-approved cannabis-derived medication.

Devinsky et al., New England Journal of Medicine, 2017

Devinsky et al., New England Journal of Medicine, 2017

View as image

If your child had hundreds of seizures a week and nothing worked, you would try anything. That is not a hypothetical. It is the reality that thousands of families with severe epilepsy have faced, and it is the reason cannabis medicine has its most compelling success story. The connection between cannabis, epilepsy, CBD, and Epidiolex is not just a medical curiosity. It is the foundation of everything that followed in legal medical cannabis.

This article covers how a little girl in Colorado changed federal drug policy, what the clinical trials actually showed, why Epidiolex is different from the CBD at your local shop, and what this single case study means for the broader conversation about cannabis as medicine.

Charlotte Figi and the Story That Changed Everything

Balanced & Benefits

Epidiolex: The Clinical Trial Results

Dravet Syndromen=120

39% seizure reduction vs 13% placebo

Devinsky et al. 2017 (NEJM)· Double-blind, placebo-controlled RCT

Lennox-Gastautn=225

Significant drop-seizure reduction at 10mg and 20mg/kg

Devinsky et al. 2018 (NEJM)· Double-blind, placebo-controlled RCT

Epidiolex vs. dispensary CBD:

Precise dosingYes — pharmaceutical gradeNo — varies by batch

Label accuracy100% — FDA-regulated31% accurate (JAMA 2017)

Contaminant testingFull FDA testingVaries by state

Insurance coverageOften coveredNever covered

Source: Devinsky et al. NEJM (2017, 2018)Epidiolex: The Clinical Trial Results

Charlotte Figi was born in 2006 in Colorado Springs. By three months old, she began having seizures. By age two, she was diagnosed with Dravet syndrome, a rare and catastrophic form of epilepsy caused by a genetic mutation affecting sodium channels in the brain. Children with Dravet syndrome experience frequent, prolonged seizures that resist nearly every available medication.

By age five, Charlotte was having up to 300 seizures per week. Her parents had tried every approved antiepileptic drug. They had tried a ketogenic diet (a strict high-fat, low-carbohydrate diet sometimes used for treatment-resistant epilepsy). They had tried experimental medications. Nothing worked for long. Charlotte had lost the ability to walk, talk, and eat. Her heart had stopped multiple times.

In 2012, Charlotte's mother Paige began researching cannabis after reading a case study about a child in another state. She connected with the Stanley brothers, cannabis growers in Colorado who had been developing a high-CBD, low-THC cannabis strain. They provided Charlotte with an oil extract from this strain.

The results were dramatic. Charlotte went from 300 seizures per week to roughly two or three per month. She began walking again. She began talking again. The strain was renamed "Charlotte's Web" in her honor.

Charlotte's story, covered in a 2013 CNN documentary by Dr. Sanjay Gupta, did more than any clinical trial to shift public opinion about medical cannabis. Families of children with severe epilepsy began relocating to Colorado to access CBD oil, a migration the media called "marijuana refugees." State legislatures across the country began passing CBD-specific laws, even in states that had rejected broader medical cannabis legalization.

Charlotte Figi passed away in 2020 at age 13, from complications likely related to COVID-19. Her legacy is the reason most Americans know the term CBD.

What Is Dravet Syndrome

Dravet syndrome affects roughly 1 in 15,700 births. It is caused by mutations in the SCN1A gene, which provides instructions for making a specific sodium channel protein that helps brain cells fire properly. When this protein does not work correctly, brain cells misfire, producing seizures.

What makes Dravet syndrome so devastating is that it resists treatment. Standard antiepileptic drugs, which work by calming overactive electrical signaling in the brain, often fail. Some medications actually make Dravet seizures worse. Children with Dravet syndrome face not just frequent seizures but developmental delays, cognitive impairment, and a significantly elevated risk of sudden unexpected death in epilepsy (SUDEP).

Lennox-Gastaut Syndrome: The Other Target

Lennox-Gastaut syndrome (LGS) is another severe form of childhood epilepsy, accounting for roughly 2-5% of all childhood epilepsies. LGS involves multiple seizure types, intellectual disability, and a distinctive pattern on EEG (the test that measures electrical activity in the brain). Like Dravet syndrome, LGS is notoriously difficult to treat. Many patients continue to have seizures despite taking multiple medications simultaneously.

Both conditions share a critical feature: they represent epilepsy at its most treatment-resistant, which is precisely why they became the testing ground for CBD.

The Clinical Trials: What Epidiolex Actually Proved

The story of Charlotte Figi was powerful, but anecdotes do not get drugs approved. The FDA requires randomized, double-blind, placebo-controlled clinical trials, the gold standard of medical evidence. And this is where the epilepsy story becomes genuinely remarkable, because the trials delivered.

The Devinsky 2017 Trial (Dravet Syndrome)

The landmark study was led by Dr. Orrin Devinsky and published in the New England Journal of Medicine in May 2017. This was a randomized, double-blind, placebo-controlled trial involving 120 children and young adults with Dravet syndrome.

Participants received either pharmaceutical-grade CBD (at a dose of 20 mg per kilogram of body weight per day) or a placebo for 14 weeks, in addition to their existing antiepileptic medications.

The results: the CBD group experienced a median reduction in convulsive seizure frequency of 39%, compared to 13% in the placebo group. Five percent of patients in the CBD group became completely seizure-free during the treatment period, compared to zero in the placebo group.

Those numbers deserve context. A 39% reduction in seizures may not sound transformative on paper. But for a child having dozens of seizures per day, reducing that frequency by more than a third, on top of whatever their other medications are achieving, is a significant improvement in quality of life. For the families who had tried everything and watched everything fail, this was the first rigorous evidence that something could work.

The Lennox-Gastaut Trials

Two additional trials, published in the New England Journal of Medicine and The Lancet in 2018, tested CBD in Lennox-Gastaut syndrome. The first trial, involving 225 patients, found that CBD at 20 mg/kg/day reduced the frequency of "drop seizures" (sudden loss of muscle tone causing falls) by a median of 44%, compared to 22% with placebo. The second trial confirmed these results at both the 20 mg/kg and 10 mg/kg dose levels.

Across all three trials, the pattern was consistent. CBD produced statistically significant and clinically meaningful reductions in seizure frequency for two of the most treatment-resistant forms of epilepsy. The effect was real. It was reproducible. And it was large enough to matter.

Side Effects Were Real Too

The trials were honest about side effects. The most common adverse effects in the CBD groups included somnolence (sleepiness, reported in roughly 25% of patients), decreased appetite, diarrhea, and elevated liver enzymes. The liver enzyme elevations were particularly notable in patients also taking valproate, another common antiepileptic drug, and required monitoring with blood tests.

These side effects are worth noting because they counter the popular claim that CBD is entirely without risk. Pharmaceutical CBD at therapeutic doses has a real side effect profile. It is manageable, but it is not zero.

FDA Approval: What Epidiolex Is and Is Not

In June 2018, the FDA approved Epidiolex (cannabidiol) oral solution for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years of age and older. In 2020, the approval was expanded to include seizures associated with tuberous sclerosis complex, another genetic condition.

This was historic for several reasons. Epidiolex became the first FDA-approved medication derived directly from the cannabis plant. It was also the first approval of any kind for Dravet syndrome specifically.

But there is a critical distinction that often gets lost. Epidiolex is not "CBD oil." It is a pharmaceutical product manufactured under strict quality controls with a precisely standardized concentration of cannabidiol. Every bottle contains exactly what the label says. The manufacturing process removes other cannabinoids and plant compounds, producing a purified CBD product.

This matters enormously because the CBD products sold at dispensaries, health food stores, and online retailers are an entirely different category.

Epidiolex vs. Dispensary CBD: Why the Difference Matters

The gap between Epidiolex and the average CBD product you can buy is not a minor technicality. It is a fundamental difference in what you are actually consuming. Understanding the difference between CBD and THC is a starting point, but the variation within CBD products themselves is just as important.

Purity and consistency. Epidiolex is manufactured to pharmaceutical standards. Every batch is tested and verified. A 2017 study published in JAMA found that of 84 CBD products purchased online, only 31% were accurately labeled. Some contained significantly less CBD than advertised. Some contained significantly more. Some contained detectable levels of THC that were not listed on the label at all.

Dosing precision. The clinical trials used a specific dose (20 mg per kilogram of body weight per day) of a specific formulation. When someone purchases a CBD tincture from a dispensary and takes a dropper full, they are guessing at the dose. They may also be consuming a full-spectrum product containing other cannabinoids, terpenes, and plant compounds that were not present in the clinical trials.

Regulatory oversight. Epidiolex is regulated by the FDA. Most other CBD products are sold as supplements or hemp products and are not subject to the same quality requirements. There is no guarantee that what is on the label matches what is in the bottle.

This does not mean dispensary CBD is useless. It means that pointing to the Epidiolex clinical trials as evidence that your CBD gummies will produce similar results is a logical error. The product is different, the dose is different, the purity is different, and the oversight is different.

Why Epilepsy Is the Strongest Case for Cannabis Medicine

If you want to understand the landscape of medical benefits of cannabis, epilepsy is the place to start. Not because it is the most common use case (chronic pain claims that title) but because the evidence quality is the highest.

Here is what makes the epilepsy evidence stand apart from most other medical cannabis claims:

Randomized controlled trials. Most medical cannabis evidence comes from observational studies, case reports, or surveys. The Epidiolex trials were proper randomized, double-blind, placebo-controlled trials, the same standard used to approve any other prescription medication.

Large, replicable effects. The seizure reductions were substantial enough to reach statistical significance with moderate sample sizes, and the results were replicated across multiple independent trials. Many cannabis studies for other conditions show small effects in small samples that have not been replicated.

FDA approval. No other condition has produced evidence strong enough to result in FDA approval of a plant-derived cannabis medication. This is not a technicality. It means the evidence survived the most rigorous regulatory review process in the world.

Biological plausibility. Researchers have identified specific mechanisms by which CBD may reduce seizures, including modulation of GPR55 receptors and TRPV1 channels (both involved in neuronal excitability). This is different from many other medical cannabis claims where the proposed mechanism is vague. The endocannabinoid system is involved in regulating neuronal firing throughout the brain, which provides a clear pathway for how CBD could affect seizure activity.

What This Means for the Broader Medical Cannabis Conversation

The Epidiolex story is sometimes used to argue that cannabis is medicine and therefore should be available for everything. That is a misuse of the evidence. What the epilepsy research actually shows is more nuanced and more useful.

It shows that specific cannabinoid compounds, at specific doses, for specific conditions, can produce meaningful clinical benefits when tested rigorously. It also shows that the distance between "this compound has potential" and "this product works for this condition" is enormous. It took years of research, millions of dollars in clinical trials, and a pharmaceutical manufacturing process to turn Charlotte Figi's anecdotal improvement into an FDA-approved medication.

That journey is the standard we should want for all medical cannabis claims. Not because the regulatory process is perfect, but because patients deserve to know that what they are taking works, at what dose, for what condition, and with what risks.

The research on CBD for anxiety, for example, is promising but nowhere near the evidence level that exists for epilepsy. Being honest about these differences does not diminish cannabis as medicine. It strengthens the case by building it on evidence rather than enthusiasm.

The Legislative Impact

Charlotte's story did not just change medicine. It changed law. Before 2013, CBD-specific legislation barely existed. After the CNN documentary aired, more than a dozen states passed laws specifically allowing CBD oil for epilepsy, even states with no broader medical cannabis program. These laws were often named after children with epilepsy, including "Charlotte's Web" laws.

The 2018 Farm Bill, which legalized hemp (cannabis containing less than 0.3% THC) at the federal level, was directly influenced by the momentum that the CBD-epilepsy story created. The reclassification of Epidiolex from Schedule I to Schedule V (the lowest restriction category) represented the first time the DEA had ever moved a cannabis-derived compound to a less restrictive schedule.

The epilepsy story demonstrated something that decades of broader legalization efforts had not: when the evidence is strong enough and the patients sympathetic enough, policy can change quickly, even around cannabis.

When to Seek Professional Help

If you or someone you know is living with epilepsy and considering CBD, do not attempt to self-treat. Epilepsy is a serious neurological condition that requires medical supervision. CBD can interact with other antiepileptic medications, particularly valproate and clobazam, in ways that require dose adjustments and blood monitoring.

Talk to a neurologist, ideally one who specializes in epilepsy. Ask specifically about Epidiolex if standard medications have not provided adequate seizure control. Do not substitute dispensary CBD products for prescribed antiepileptic medications without medical guidance.

If you are experiencing a mental health crisis or need help with any aspect of your health, SAMHSA's National Helpline is available 24/7 at 1-800-662-4357. It is free, confidential, and available in English and Spanish.

The Bigger Picture

The Epidiolex story is the best evidence that cannabis-derived compounds can be genuine medicine. It is also a case study in why the path from promising compound to proven treatment matters. Charlotte Figi's experience was real and dramatic. But it took rigorous clinical trials, pharmaceutical-grade manufacturing, and FDA review to turn that experience into something doctors could prescribe with confidence.

That distinction, between what works in one person's story and what works across hundreds of patients in controlled conditions, is the difference between hope and evidence. Both have value. But when you are making decisions about your health or the health of someone you love, evidence is what you deserve.

The Bottom Line

The cannabis-epilepsy connection produced the strongest evidence in all of medical cannabis research and the first FDA-approved cannabis-derived medication. Charlotte Figi, diagnosed with Dravet syndrome (SCN1A gene mutation, up to 300 seizures/week), went from failing every available treatment to near-seizure-freedom with high-CBD cannabis oil in 2012 — her story catalyzed nationwide CBD legislation. The Devinsky 2017 landmark trial (NEJM, 120 patients, randomized double-blind placebo-controlled) demonstrated 39% reduction in convulsive seizures vs. 13% placebo in Dravet syndrome at 20mg/kg/day pharmaceutical CBD. Two additional 2018 trials in Lennox-Gastaut syndrome showed 44% reduction in drop seizures vs. 22% placebo. FDA approved Epidiolex in June 2018 for Dravet and Lennox-Gastaut (expanded to tuberous sclerosis complex in 2020). Critical distinction: Epidiolex is purified pharmaceutical-grade CBD with precise dosing, manufactured under FDA standards — a 2017 JAMA study found only 31% of commercial CBD products were accurately labeled, with 21% containing unlisted THC. The epilepsy evidence stands apart because of: proper RCTs (not just observational data), large replicable effects across multiple independent trials, FDA approval surviving the most rigorous regulatory review, and identified biological mechanisms (GPR55/TRPV1 modulation). Side effects include somnolence (25%), decreased appetite, diarrhea, and elevated liver enzymes (especially with concurrent valproate). Legislative impact: Charlotte's story drove CBD-specific laws in 12+ states and influenced the 2018 Farm Bill legalizing hemp.

Frequently Asked Questions

Is Epidiolex the same as CBD oil from a dispensary?

No. Epidiolex is a pharmaceutical-grade, purified cannabidiol product manufactured under strict FDA quality standards. It contains a precise, verified concentration of CBD with no other cannabinoids. CBD oil from a dispensary or online retailer may contain variable amounts of CBD, other cannabinoids, and compounds not listed on the label. A 2017 JAMA study found that only 31% of commercial CBD products were accurately labeled.

Can CBD cure epilepsy?

CBD does not cure epilepsy. In the clinical trials, Epidiolex reduced seizure frequency by approximately 39-44% in patients with Dravet syndrome and Lennox-Gastaut syndrome. This is a significant reduction, but most patients continued to have some seizures. CBD is used as an add-on therapy alongside other antiepileptic medications, not as a replacement for them.

Does CBD work for all types of seizures and epilepsy?

Epidiolex is FDA-approved specifically for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. These are rare, severe, treatment-resistant forms of epilepsy. The evidence for CBD in more common forms of epilepsy is much thinner. Some preliminary studies suggest potential benefit, but rigorous clinical trials have not been completed for most other epilepsy types. Talk to a neurologist before considering CBD for any seizure condition.

Who was Charlotte Figi and why is she important to cannabis legislation?

Charlotte Figi was a Colorado girl with Dravet syndrome who experienced up to 300 seizures per week before trying a high-CBD cannabis oil in 2012. Her seizures dropped to roughly two or three per month. Her story, featured in a 2013 CNN documentary by Dr. Sanjay Gupta, catalyzed a nationwide movement that led to CBD-specific laws in dozens of states and influenced the 2018 Farm Bill that legalized hemp federally. She passed away in 2020 at age 13.

What are the side effects of Epidiolex CBD for epilepsy?

In clinical trials, the most common side effects of Epidiolex included sleepiness (in roughly 25% of patients), decreased appetite, diarrhea, and elevated liver enzymes. The liver enzyme elevations were more common in patients also taking valproate and required regular blood test monitoring. While generally manageable, these side effects demonstrate that pharmaceutical-grade CBD at therapeutic doses is not entirely risk-free.

Can adults with epilepsy use Epidiolex, or is it only for children?

Epidiolex is approved for patients two years of age and older, which includes adults. The clinical trials enrolled both children and young adults. However, most prescribing experience is in pediatric populations because Dravet and Lennox-Gastaut syndromes are typically diagnosed in childhood. Adults with treatment-resistant epilepsy should discuss Epidiolex with their neurologist, who can evaluate whether their specific seizure type and treatment history make them a candidate. The same considerations apply: potential liver enzyme interactions with other antiepileptic medications require monitoring, and the medication is prescribed as an add-on therapy alongside existing seizure medications, not as a standalone replacement.